Generating AI analysis...
Revenue
$23.47B
-2.48% YoY
EPS (Basic)
$1.85
++136.63% YoY
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $23.47B | $24.07B | -2.48% |
Cost of Revenue | $6.4B | $6.2B | +3.31% |
Net Income | $3.77B | $-10.23B | +136.81% |
EPS (Basic) | $1.85 | $-5.05 | +136.63% |
EPS (Diluted) | $1.85 | $-5.05 | +136.63% |
R&D Expense | $4.84B | $5.59B | -13.53% |
SG&A Expense | $3.3B | $4.29B | -23.24% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $94.68B | $94.65B | +0.03% |
Current Assets | $33.22B | $26.89B | +23.55% |
Total Liabilities | $77.19B | $77.58B | -0.50% |
Current Liabilities | $27.53B | $23.27B | +18.32% |
Stockholders' Equity | $17.43B | $17.02B | +2.47% |
Cash & Equivalents | $12.6B | $6.29B | +100.21% |
Long-Term Debt | $48.95B | $51.95B | -5.78% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $5.87B | $5.16B | +13.78% |
Investing Cash Flow | $-972M | $-20.94B | +95.36% |
Financing Cash Flow | $-2.83B | $10.62B | -126.64% |
Dividends Paid | $2.52B | $2.43B | +3.75% |
D&A | $2.02B | $5.13B | -60.55% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 16.0% | — | — |
ROE | 21.6% | — | — |
ROA | 4.0% | — | — |
Current Ratio | $1.207 | — | — |
Debt to Equity | $4.427 | — | — |
Other companies in Pharmaceuticals